A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants
A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ETX0282 Administered in Healthy Subjects
Sponsor: Entasis Therapeutics
This PHASE1 trial investigates Healthy Volunteers and is currently completed. Entasis Therapeutics leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Mar 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Sep 2018 — Mar 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Entasis Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .